Optimal radiotherapy Scientific Programme for all ESTRO ANNUAL CONFE RENCE 27 - 31 August 2021 Onsite in Madrid, Spain & Online Saturday 28 August 2021 Track: Radiobiology Teaching lecture: The microbiome: Its role in cancer development and treatment response Saturday, 28 August 2021 08:00 - 08:40 N104 Chair: Marc Vooijs - 08:00 The microbiome: Its role in cancer development and treatment response SP - 0004 A. Facciabene (USA) Track: Clinical Teaching lecture: Breast reconstruction and radiotherapy Saturday, 28 August 2021 08:00 - 08:40 Plenary Chair: Philip Poortmans - 08:00 Breast reconstruction and radiotherapy SP - 0005 O. Kaidar-Person (Israel) Track: Clinical Teaching lecture: Neurocognitive changes following radiotherapy for primary brain tumours Saturday, 28 August 2021 08:00 - 08:40 Room 1 Chair: Brigitta G. Baumert - 08:00 Evaluation and care of neurocognitive effects after radiotherapy SP - 0006 M. Klein (The Netherlands) 08:20 Imaging biomarkers of dose-induced damage to critical memory regions SP - 0007 A. Laprie (France Track: Physics Teaching lecture: Independent dose calculation and pre-treatment patient specific QA Saturday, 28 August 2021 08:00 - 08:40 Room 2.1 Chair: Kari Tanderup - 08:00 Independent dose calculation and pre-treatment patient specific QA SP - 0008 P. Carrasco de Fez (Spain) 1 Track: Physics Teaching lecture: Diffusion MRI: How to get started Saturday, 28 August 2021 08:00 - 08:40 Room 2.2 Chair: Tufve Nyholm - Chair: Jan Lagendijk - 08:00 Diffusion MRI: How to get started SP - 0009 R. Tijssen (The Netherlands) Track: RTT Teaching lecture: The role of RTT leadership in advancing multi-disciplinary research Saturday, 28 August 2021 08:00 - 08:40 N103 Chair: Sophie Perryck - 08:00 The role of RTT leadership in advancing multi-disciplinary research SP - 0010 M. Velec (Canada) Track: Brachytherapy Teaching lecture: New developments In skin cancers treatment: is brachytherapy the new frontier especially for the face? Saturday, 28 August 2021 08:00 - 08:40 N105-N106 Chair: Luca Tagliaferri - 08:00 New developments In skin cancers treatment: is brachytherapy the new frontier SP - 0011 especially for the face? P. Wojcieszek (Poland) Track: Interdisciplinary Symposium: Education in radiation oncology Saturday, 28 August 2021 08:45 - 10:00 N101-102 Chair: Jesper Grau Eriksen & TBC - 08:45 ESTRO Curricula done and published - Now what? SP - 0012 M. Giuliani (Canada) 2 09:03 How to design a training programme that actually train the resident SP - 0013 B. Millar (Canada) 09:21 Does work-place based assessment deliver on its promise? SP - 0014 S. Turner (Australia) 09:39 The trainee perspective - What do we really need for good training? SP - 0015 J. Heukelom (The Netherlands) Track: Radiobiology Joint symposium: ESTRO-EACR: How does cancer cell metabolism affect the radiation response and vice versa? Saturday, 28 August 2021 08:45 - 10:00 N104 Chair: Caroline Dive - Chair: Anthony Chalmers - 08:48 Tumour metabolic adaptations as biomarkers for radiation oncology SP - 0016 O. Maddocks (United Kingdom) 09:06 Application of metabolic imaging for the predication and assessment of treatment SP - 0017 response J. Bussink (The Netherlands) 09:24 Radiation-driven tumour metabolic reprogramming SP - 0018 T. Burns (UK) 09:42 Targeting tumour metabolism for enhancing radiotherapy response SP - 0019 L. Kunz-Schughart (Germany Track: Clinical Symposium: New endpoints for early breast cancer - Less is more? Saturday, 28 August 2021 08:45 - 10:00 Plenary Chair: Elisabetta Bonzano - Chair: Dorota Gabrys - 08:45 Health-related quality of life - Primary or surrogate endpoint? SP - 0020 I. Meattini (Italy) 3 09:03 Less surgery or less radiation therapy in early stage breast cancer? SP - 0021 P. Poortmans (Belgium) 09:21 Tumour bed boost in breast cancer - When, whom, how? SP - 0022 M. Krause (Germany) 09:39 Less endocrine therapy for very low-risk patients? SP - 0023 E. Nowicka (Poland) Track: Clinical Symposium: Radiosurgery for central nervous system disorders: Beyond glioblastoma and metastases Saturday, 28 August 2021 08:45 - 10:00 Room 1 Chair: Sławomir Blamek - Chair: Maximilian Niyazi - 08:45 Radiotherapy for vestibular schwannoma and meningioma SP - 0024 E. Herrmann (Switzerland) 09:03 SRS for Parkinson's disease and trigeminal neuralgia - in memoriam Leszek SP - 0025 Miszczyk L. Miszczyk (Poland), G. Głowacki, A. Roch-Zniszczoł, D. Larysz, M. Stąpór-Fudzińska, B. Goc, S. Blamek, A. Rożek 09:21 Primary and repeat radiosurgery for functioning and nonfunctioning pituitary SP - 0026 adenoma G. Minniti (Italy) 09:39 Can we treat epilepsy and obsessive-compulsive disorder with radiation? SP - 0027 Sameer Sheth (USA) Track: Physics Symposium: Clinical implementation of in vivo dosimetry Saturday, 28 August 2021 08:45 - 10:00 Room 2.1 Chair: Elise Konradsson - Chair: Cristina Garibaldi - 4 08:45 Large scale clinical implementation of in vivo dosimetry - What value does it SP - 0028 bring? E. Bossuyt (Belgium) 09:10 In vivo dosimetry in EBRT: Requirements and future directions for research, SP - 0029 development, and clinical practice I. Olaciregui Ruiz (The Netherlands) 09:35 In vivo dosimetry in brachytherapy: Requirements and future directions for SP - 0030 research, development and clinical practice K. Tanderup (Denmark), G. Fonseca, J.G. Johansen, R. Smith, L. Beaulieu, S. Beddar, G. Kertzscher, F. Verhaegen Track: Physics Symposium: The use of MR in radiotherapy Saturday, 28 August 2021 08:45 - 10:00 Room 2.2 Chair: Marielle Philippens, Uulke van der Heide & Emilia Persson - 08:45 Does MR-only treatment planning live up to its expectations? SP - 0147 T. Nyholm (Sweden) 09:10 Real-time adaptation under MR-guidance SP - 0148 J. Bertholet (Switzerland) 09:35 A roadmap for imaging biomarker studies on MR-linac systems SP - 0149 P. van Houdt (The Netherlands) Track: RTT Symposium: RTT-led radiomics research Saturday, 28 August 2021 08:45 - 10:00 N103 Chair: Ingrid Kristensen - Chair: Sophie Perryck - 08:45 Personalised breast cancer treatment using radiomics SP - 0035 W. Tran (Canada) 5 09:10 MR radiomics in prostate cancer SP - 0036 M. Leech (Ireland) 09:35 Head and neck radiomics in a toxicity prediction model SP - 0037 A. Duffton (United Kingdom), W. Nailon, T. Berger, D. Noble, C. Paterson Track: Brachytherapy Debate: Prostate cancer: Short treatments by SBRT or brachytherapy? Saturday, 28 August 2021 08:45 - 10:00 N105-N106 Chair: Barbara Jereczek-Fossa - Chair: Carl Salembier - 08:45 SBRT SP - 0038 G. Marvaso (Italy) 09:10 Brachy SP - 0039 P. Hoskin (United Kingdom) 09:35 Rebuttals + Discussion SP - 0040 Track: Physics Poster highlights: Poster Highlights 1: Treatment planning 1 Saturday, 28 August 2021 08:45 - 09:45 Online Stream 1 Chair: Christopher Kurz - 08:45 Introducing a probabilistic target presence in expected-value optimization PH - 0041 G. Buti (Belgium), K. Souris, A.M. Barragan-Montero, J.A. Lee, E. Sterpin 08:53 Dosimetric impact of auto segmentation on treatment planning in IMRT for PH - 0042 prostate patients M. Kawula (Germany), D. Purice, M. Li, G. Vivar, S. Ahmadi, K. Parodi, C. Belka, G. Landry, C. Kurz 6 09:01 Robustness of Wide Tangents and VMAT through simulations and CBCT PH - 0043 delivered dose in breast cancer I. Gleeson (United Kingdom), M. Toomey, K. Hutchinson, H. Chantler 09:09 Robust planning of VMAT for breast cancer including loco-regional lymph nodes PH - 0044 M. Kjeldsen (Denmark) 09:17 Comparing robustness of margin and robustly optimised plans to anatomical PH - 0045 deformations in H&N J. Robbins (United Kingdom), E. Vasquez Osorio, A. Green, M. van Herk 09:25 Benefit of 4D robustly optimized proton plans for NSCLC patients with PH - 0046 intrafractional motion > 5mm S. Spautz (Germany), L. Haase, M. Tschiche, S. Makocki, E.G. Troost, C. Richter, K. Stützer 09:33 CTV and OAR robustness of clinical neuro IMPT: dosimetric impact of the PH - 0047 DUPROTON robustness protocol J. Rojo Santiago (The Netherlands), S.J. Habraken, D. Lathouwers, A. Méndez Romero, Z. Perkó, M.S. Hoogeman Track: Clinical Poster highlights: Poster Highlights 2: Head and neck 1 Saturday, 28 August 2021 08:45 - 09:45 Online Stream 2 Chair: Pierluigi Bonomo - 08:45 Pattern of failure after curative (C-)RT in HNSCC: data from the phase III PH - 0048 DAHANCA19 study M.H. Kristensen (Denmark), C.R. Hansen, R. Zukauskaite, A.I.S. Holm, E.S. Hinsby, C. Maare, J. Johansen, H. Primdahl, Å. Bratland, C.A. Christensen, M. Andersen, J. Overgaard, J.G. Eriksen 08:53 Reduction of GTV to CTV radiation margin in head and neck squamous cell PH - 0049 carcinoma is oncological safe and significantly reduced acute and late radiation- related toxicity A. Al-Mamgani (The Netherlands), R. Kessels, A. Navran, O. Hamming-Vrieze, C.L. Zuur, J.P. de Boer, M.C. Jonker, T. Janssen, J. Sonke, C.A. Marijnen 09:01 Detailed analysis of lymphatic progression patterns for oropharyngeal squamous PH - 0050 cell carcinoma B. Pouymayou (Switzerland), J. Hoffmann, R. Ludwig, M. Guckenberger, P. Balermpas, J. Unkelbach 7 09:09 Outcomes after definitive (C)RT in HPV+ OPC: Largescale comparison of two PH - 0051 population-based cohorts P. Lassen (Denmark), S.H. Huang, J. Su, B. O'Sullivan, J. Waldron, M. Andersen, H. Primdahl, J. Johansen, C. Andrup Kristensen, E. Andersen, J. Eriksen, C. Rønn Hansen, J. Alsner, J. Lilja-Fisher, S. V. Bratman, J. Ringash, J. Kim, A. Hope, A. Spreafico, J. de Almeida, W. Xu, J. Overgaard 09:17 Do head and neck cancer patients in randomized trials represent the population PH - 0052 in daily practice? J. Kaanders (The Netherlands), S. van den Bosch, J. Kleijnen 09:25 NBTXR3 activated by SBRT combined with nivolumab or pembrolizumab in PH - 0053 advanced cancers: phase I trial C. Shen (USA), J. Frakes, J. Niu, A. Rosenberg, J. Weiss, J. Caudell, K. Jameson, P. Said, T. Seiwert 09:33 Re-Irradiation in head & neck cancer - a pooled analysis of 253 individual cases PH - 0054 J.